secwatch.observer — SEC 8-K summary
======================================

Issuer:     EVOME MEDICAL TECHNOLOGIES INC. (—)
CIK:        0001617765
Form:       8-K
Filed at:   2023-04-07T23:59:59+00:00
Accession:  0001062993-23-008942
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 2.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Salona Global closes Biodex acquisition for $8M; reports 167% revenue growth to $33.6M
--------------------------------------------------------------------------------

- Acquired Biodex for $1M cash + $7M in installments; adds projected $26M annual revenue at ~30% gross margin.
- Transition period revenue $33.6M (167% YoY growth); gross margin $10.6M (31.4% of revenue).
- Adjusted EBITDA $435,948 (17% YoY growth); preliminary Feb 2023 revenue ~$6.7M, EBITDA ~$200K.
- Combined annualized revenue estimated at ~$65M with ~34% gross margin; order backlog ~$20M.
- Appointed Joe Martinez as SVP, Legal & Compliance, General Counsel effective March 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1617765/000106299323008942/0001062993-23-008942-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1617765/000106299323008942/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001062993-23-008942

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer